Zoetis Inc. (NYSE:ZTS) Stake Reduced by Jacobs & Co. CA

Jacobs & Co. CA trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 83,221 shares of the company’s stock after selling 703 shares during the quarter. Zoetis comprises about 1.9% of Jacobs & Co. CA’s holdings, making the stock its 9th biggest holding. Jacobs & Co. CA’s holdings in Zoetis were worth $16,425,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. State Street Corp boosted its holdings in shares of Zoetis by 1.1% during the 2nd quarter. State Street Corp now owns 19,630,557 shares of the company’s stock valued at $3,380,578,000 after acquiring an additional 213,907 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Zoetis by 2.5% during the 3rd quarter. Wellington Management Group LLP now owns 12,344,692 shares of the company’s stock valued at $2,147,730,000 after acquiring an additional 297,044 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Zoetis by 34.6% during the 4th quarter. Morgan Stanley now owns 10,872,704 shares of the company’s stock valued at $1,593,395,000 after acquiring an additional 2,796,694 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Zoetis by 0.3% during the 1st quarter. Geode Capital Management LLC now owns 9,739,370 shares of the company’s stock valued at $1,617,464,000 after acquiring an additional 27,097 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Zoetis by 3.3% during the 3rd quarter. Northern Trust Corp now owns 6,143,258 shares of the company’s stock valued at $1,068,804,000 after acquiring an additional 196,771 shares during the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction that occurred on Thursday, January 18th. The shares were sold at an average price of $191.43, for a total transaction of $176,689.89. Following the sale, the executive vice president now owns 17,569 shares in the company, valued at $3,363,233.67. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders have sold a total of 2,209 shares of company stock worth $408,453 over the last quarter. Insiders own 0.12% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $168.51 on Thursday. Zoetis Inc. has a 12 month low of $151.03 and a 12 month high of $201.92. The stock has a market cap of $77.16 billion, a price-to-earnings ratio of 33.24, a PEG ratio of 2.53 and a beta of 0.87. The company’s 50 day moving average is $186.36 and its two-hundred day moving average is $182.34. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter in the previous year, the business posted $1.15 EPS. Zoetis’s revenue was up 8.5% on a year-over-year basis. As a group, research analysts anticipate that Zoetis Inc. will post 5.8 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a dividend yield of 1.03%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is currently 34.12%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ZTS. The Goldman Sachs Group raised their price target on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Piper Sandler raised their price objective on shares of Zoetis from $215.00 to $220.00 and gave the stock an “overweight” rating in a report on Tuesday, February 20th. Stifel Nicolaus raised their price objective on shares of Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, January 12th. BNP Paribas initiated coverage on shares of Zoetis in a report on Thursday, December 7th. They issued an “outperform” rating and a $237.00 price objective on the stock. Finally, Barclays raised their price objective on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, February 14th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $224.33.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.